Literature DB >> 17455148

Expression of TFF3 during multistep colon carcinogenesis.

R John1, N M El-Rouby, C Tomasetto, M-C Rio, S M Karam.   

Abstract

The pathogenesis of colon cancer is not well understood. This common type of cancer is generally believed to occur in a multistep process which involves alterations of various tumor suppressor genes and oncogenes during the progression through benign lesions towards carcinoma. TFF3 is a product of the colonic epithelium and has been implicated in colonic mucosal protection and also in the aggressiveness of colon cancer cells. The aim of this study was to analyze the expression of TFF3 during propagation towards cancer development in the human colon. Colonic tissues representing colitis, adenomatous polyposis, tubulovillous adenoma, and mucoid/adeno-carcinomas were processed for immunohistochemistry using an antibody specific for human TFF3. The results were correlated with those of PCNA-labeling, quantified, and compared with those of control tissues obtained from the safe margin of macroscopically normal colonic mucosa of patients with colon cancer. The data showed marked down-regulation of TFF3 expression in adenomatous polyposis, then TFF3 expression returns to about control level during adenoma and remains high during mucoid- and adeno-carcinomas. Colonic tissues with highly invasive cancer cells were characterized by statistically significant down-regulation of TFF3 expression. The changes observed in expression of TFF3 showed an inverse correlation with cell proliferation and suggest that it might play a protective role against colon carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17455148     DOI: 10.14670/HH-22.743

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  9 in total

1.  Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors.

Authors:  Michal Mikula; Tymon Rubel; Jakub Karczmarski; Krzysztof Goryca; Michal Dadlez; Jerzy Ostrowski
Journal:  Funct Integr Genomics       Date:  2010-11-09       Impact factor: 3.410

2.  TFF3 and HER2 expression and their correlation with survival in gastric cancer.

Authors:  Jianchun Gu; Leizhen Zheng; Li Zhang; Siyu Chen; Meiling Zhu; Xiaoping Li; Yajie Wang
Journal:  Tumour Biol       Date:  2014-12-17

3.  Dynamic tumor growth patterns in a novel murine model of colorectal cancer.

Authors:  Terrah J Paul Olson; Jamie N Hadac; Chelsie K Sievers; Alyssa A Leystra; Dustin A Deming; Christopher D Zahm; Dawn M Albrecht; Alice Nomura; Laura A Nettekoven; Lauren K Plesh; Linda Clipson; Ruth Sullivan; Michael A Newton; William R Schelman; Richard B Halberg
Journal:  Cancer Prev Res (Phila)       Date:  2013-11-06

4.  Relationship between expression of gastrin, somatostatin, Fas/FasL and caspases in large intestinal carcinoma.

Authors:  Jia-Ding Mao; Pei Wu; Ying-Lin Yang; Jian Wu; He Huang
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

5.  Identification and validation of genes involved in cervical tumourigenesis.

Authors:  Thangarajan Rajkumar; Kesavan Sabitha; Neelakantan Vijayalakshmi; Sundersingh Shirley; Mayil Vahanan Bose; Gopisetty Gopal; Ganesharaja Selvaluxmy
Journal:  BMC Cancer       Date:  2011-02-22       Impact factor: 4.430

6.  Downregulation of trefoil factor-3 expression in the rectum is associated with the development of ulcerative colitis-associated cancer.

Authors:  Satoru Kondo; Toshimitsu Araki; Yuji Toiyama; Koji Tanaka; Mikio Kawamura; Yoshinaga Okugawa; Yoshiki Okita; Susumu Saigusa; Yasuhiro Inoue; Keiichi Uchida; Yasuhiko Mohri; Masato Kusunoki
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

7.  Trefoil Factor 3 Inhibits Thyroid Cancer Cell Progression Related to IL-6/JAK/STAT3 Signaling Pathway.

Authors:  Yunchao Xin; Xiaoling Shang; Xiaoran Sun; Yachao Liu; Guogang Xu; Gang Xue
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-14       Impact factor: 2.629

8.  CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression.

Authors:  Hong-Yong Cui; Shi-Jie Wang; Fei Song; Xu Cheng; Gang Nan; Yu Zhao; Mei-Rui Qian; Xi Chen; Jia-Yue Li; Fen-Ling Liu; Yu-Meng Zhu; Ruo-Fei Tian; Bin Wang; Bin Wu; Yang Zhang; Xiu-Xuan Sun; Ting Guo; Xiang-Min Yang; Hai Zhang; Ling Li; Jing Xu; Hui-Jie Bian; Jian-Li Jiang; Zhi-Nan Chen
Journal:  Signal Transduct Target Ther       Date:  2021-07-14

9.  Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK.

Authors:  Ru-Mei Chen; Yi-Shiou Chiou; Qing-Yun Chong; Han-Ming Poh; Tuan-Zea Tan; Meng-Yi Zhang; Lan Ma; Tao Zhu; Vijay Pandey; Alan Prem Kumar; Peter E Lobie
Journal:  Int J Mol Sci       Date:  2019-12-09       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.